Leishmaniasis Clinical Presentation
- Author: Craig G Stark, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
Although the Leishmania species differ clinically and biologically, their characteristics overlap and each clinical syndrome can be produced by multiple species of Leishmania.
The broad spectrum of clinical manifestations of cutaneous leishmaniasis is often compared with that of leprosy. Cutaneous leishmaniasis can be simple or diffuse (disseminated). Different species, as well as host factors, can also affect the clinical picture, in which some species cause "wet" ulcers and others "dry" ulcers.
The hallmark of cutaneous leishmaniasis is skin lesions, which can spontaneously heal in 2-10 months. Inoculation occurs after a sandfly bites an exposed part of the body (usually the legs, arms, neck, or face). Incubation occurs over weeks to months, followed by the appearance of an erythematous papule, which can evolve into a plaque or ulcer. These lesions are usually painless.
No systemic symptoms are evident. After recovery or successful treatment, cutaneous leishmaniasis induces immunity to reinfection by the species of Leishmania that caused the disease.
Localized cutaneous disease
Both New World and Old World species cause localized cutaneous leishmaniasis. New World disease usually presents with a solitary nodule, whereas Old World disease is associated with multiple lesions. Systemic symptoms are absent. Wound progression occurs over time and may exhibit localized lymphangitic spread. See the images below.
The lesions are usually without pain or pruritus, although secondary bacterial infection may complicate the wound (see the following image). Healing may occur spontaneously over 2-12 months and is followed by scarring and changes in pigmentation. New World disease may progress to mucocutaneous leishmaniasis.
Diffuse cutaneous leishmaniasis
Diffuse cutaneous disease develops in an anergic host with poor immune response. This condition is associated with a deficient cell-mediated immunity that enables the parasite to disseminate in the subcutaneous tissues and has been reported in patients with human immunodeficiency virus (HIV) infection.
Infection is characterized by a primary lesion, which slowly spreads to involve multiple areas of the skin (face, ears, extremities, buttocks) until the whole body is affected. Plaques, ulcers, and nodules may form over the entire body, resembling lepromatous leprosy (see the image below). However, no neurologic or systemic invasion is involved; as a result, although the lesions are neither destructive nor erosive, they are disfiguring. The infections are chronic and may recur after treatment.
Although diffuse disease is more common with New World species in Central and South America, Old World L aethiopica may progress to diffuse disease in East Africa.
Leishmaniasis recidivans may occur years after a localized cutaneous lesion has healed, commonly presenting on the face (see the following image). New ulcers and papules form over the edge of the old scar and proceed inward to form a psoriasiform lesion. Infection may be from reactivation of dormant parasites or new infection from a different species. Skin trauma can result in activation of seemingly latent cutaneous infection long after the initial bite. The infections tend to be resistant to treatment.
Post-kala-azar dermal leishmaniasis
Post-kala-azar dermal leishmaniasis follows the treatment of visceral leishmaniasis and has predominantly been described in Africa (about 2% of cases) and India (about 10% of cases).
The Indian variant occurs in patients 1-2 years and as long as 20 years after recovery from visceral leishmaniasis. This condition is characterized by multiple, hypopigmented, erythematous macules. Over time, these macules can transform into large nontender plaques and nodules that involve the face and trunk (see the image below). The disease resembles lepromatous leprosy and requires intensive therapy. The African variant occurs shortly after treatment of visceral leishmaniasis and is characterized by an erythematous papular rash on the face, buttocks, and extremities. These lesions spontaneously resolve over the course of several months.
In Sudan, patients often present with a facial rash consisting of small papules resembling measles that spreads to involve other parts of the body. This syndrome may heal spontaneously, but relapse is common. Established disease is generally difficult to treat.
Post–kala-azar dermal leishmaniasis that is resistant to antimonial agents has been reported, with an incidence rate of 1 in 700 cases.
Mucocutaneous disease, also called espundia in South America, usually develop by metastasis from disseminated protozoa rather than by local spread. This condition is most commonly caused by New World species, although Old World L aethiopica has also been reported to cause this syndrome. Secondary infection plays a prominent role in the size and persistence of ulcers.
Infection by L (Viannia) braziliensis may lead to mucosal involvement in up to 10% of infections, depending on the region in which it was acquired. The incubation period is from 1 to 3 months. The initial infection is characterized by a persistent cutaneous lesion that eventually heals, although as many as 30% of patients report no prior evidence of leishmaniasis.
Ulcer progression is slow and steady. Several years later, oral and respiratory mucosal involvement occurs, causing inflammation and mutilation of the nose, mouth, oropharynx, and trachea (see the following image), resulting in symptoms of nasal obstruction and bleeding. These can become sites of infection, sometimes leading to sepsis. Cases in which the time between the primary lesion and the appearance of mucosal involvement is up to 2 decades have been reported.
Progressive mucocutaneous disease is difficult to treat and often recurs. With prolonged infection, death occurs from respiratory compromise and malnutrition. Mucocutaneous leishmaniasis may arise after inadequate treatment of certain Leishmania species.
Children are rarely affected.
Visceral disease, the most devastating and fatal form of leishmaniasis, is classically known as kala-azar or the Indian name for “black fever/disease,” which is a reference to the characteristic darkening of the skin that is seen in patients with this condition. Other terms used to describe visceral disease include Dumdum fever, Assam fever, and infantile splenomegaly in various parts of the world.
This condition occurs with both New and Old World species and results from systemic infection of the liver, spleen, and bone marrow. The spectrum of illness ranges from asymptomatic infection or self-resolving disease to fulminant, severe, life-threatening infection; many subclinical cases occur and go unrecognized for each clinically recognized case.
The syndrome is characterized by the pentad of fever, weight loss, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. The fever is continuous or remittent and becomes intermittent at a later stage. It is also characteristically described as a double rise in 24 hours, in which waves of pyrexia may be followed by a period without fever. Patients may also report night sweats, weakness, diarrhea, malaise, and anorexia. Melanocyte stimulation and xerosis can occur, causing characteristic skin hyperpigmentation.
Onset of visceral disease can be insidious or sudden. The incubation period varies after infection (usually 3-6 mo, but can be months or years) and may depend on the patient's age and immune status as well as the species of Leishmania. Young malnourished children are most susceptible to developing progressive infection; those who present later in the course of the disease may present with edema caused by hypoalbuminemia, hemorrhage caused by thrombocytopenia, or growth failure caused by features of chronic infection.
If visceral disease is left untreated, death frequently occurs within 2 years which may be due to hemorrhage (secondary to infiltration of the hematopoietic system), severe anemia, immunosuppression, and/or secondary infections.
A variant of visceral leishmaniasis has been described in US soldiers who participated in the Gulf War. This is associated with light parasitic burden and mild symptoms including fever, malaise, and nausea.
Viscerotropic leishmaniasis has an indolent but distinct clinical presentation and does not appear to progress to full visceral leishmaniasis. Patients have presented with an array of symptoms months to years after infection, including fever, rigors, fatigue, malaise, nonproductive cough, intermittent diarrhea, headache, arthralgias, myalgias, nausea, adenopathy, transient hepatosplenomegaly, and abdominal pain.
Although L tropica traditionally has been associated with cutaneous leishmaniasis, several reports of visceral disease have been reported from Kenya, India, and Israel. In addition, reports of patients returning from the Middle East showed presentations ranged from 1 month to 2 years after exposure, with many of symptoms described above: malaise, fatigue, intermittent fever, cough, diarrhea, abdominal pain, and other gastrointestinal symptoms.
Cutaneous disease may have the following physical manifestations:
Localized cutaneous leishmaniasis: Crusted papules or ulcers on exposed skin; lesions may be associated with sporotrichotic spread
Diffuse (disseminated) cutaneous leishmaniasis: Multiple, widespread nontender, nonulcerating cutaneous papules and nodules; analogous to lepromatous leprosy lesions
Leishmaniasis recidivans: Presents as a recurrence of lesions at the site of apparently healed disease years after the original infection, typically on the face and often involving the cheek; manifests as an enlarging papule, plaque, or coalescence of papules that heals with central scarring (ie, lesions in the center or periphery of an old healed leishmaniasis scar); relentless expansion at the periphery may cause significant facial destruction similar to the lupus vulgaris variant of cutaneous tuberculosis
Post–kala-azar dermal leishmaniasis: Develops months to years after the patient's recovery from visceral leishmaniasis, with cutaneous lesions ranging from hypopigmented macules to erythematous papules and from nodules to plaques; the lesions may be numerous and persist for decades
The presentation of cutaneous disease varies depending on the stage of disease, although it mainly occurs in 2 forms, (1) an oriental sore caused by L tropica and (2) American cutaneous leishmaniasis caused by L brasiliensis. Lesions are usually found in exposed areas (eg, face, arms, legs). The skin lesion begins as a nontender, firm, red papule several centimeters in size at the site of the sandfly bite. In time, the lesion becomes darker, widens with central ulceration, serous crusting, and granuloma formation. The border often has a raised erythematous rim known as the volcano sign. See the images below.
The lesions may be moist or open with seropurulent exudate, or the ulcers may be dry with a crusted scab and become fibrotic or hyperkeratotic with healing (after about 3-6 mo, leaving a raised border) (see the following image).
Urban cutaneous leishmaniasis, caused by a subspecies of L tropica, presents as a dry cutaneous ulcer on the face and has an urban distribution. The incubation period is approximately 2 months. It is common in Western India, North Africa, the Mediterranean region, and Middle East. A similar disease in Mexico, Honduras, and Guatemala is known as the bay sore or chiclero ulcer. It is a chronic lesion that occurs at the site of a sand fly bite.
Rural cutaneous leishmaniasis is caused by L tropica and has a rural distribution. Multiple moist cutaneous lesions appear on the extremities and are associated with marked local subcutaneous infiltration and regional lymphadenitis. Both lesions are common in Central Asia.
Other findings of cutaneous disease include eczematous, psoriasiform, varicelliform, and verrucous lesions. The area surrounding the primary lesion may exhibit lymphangitic spread with palpable cords and subcutaneous nodules. This is common in New World lesions caused by L (Viannia) braziliensis infections.
Regional adenopathy, subcutaneous nodules, and satellite lesions may be present. The lesions are usually painless and without pruritus. A generalized inflammatory reaction to migrating parasites may be present in the skin surrounding the sore. Overlying bacterial infection may complicate the natural history. Healing occurs over months to years, leaving a characteristic retracted hypopigmented scar. Untreated sores can leave depigmented retracted scars. Thus, although this form is often self-healing, it can create serious disability and permanent scars. See the images below.
Post–kala-azar dermal leishmaniasis
Post–kala-azar dermal lesions are categorized into 3 types, as follows:
Depigmented macules: The earliest lesions; present on the trunk and extremities
Erythematous patches: Appear early in the course of disease; seen on the nose, cheeks, and chin, with a butterfly distribution; they are photosensitive and become prominent toward the middle of the day
Yellowish pink nodules: Appear mostly on the face and replace the earlier lesions; the absence of ulceration distinguishes these nodules from those of cutaneous leishmaniasis (oriental sore)
Mucocutaneous leishmaniasis consists of the relentless destruction of the oropharynx and nose, resulting in extensive midfacial destruction.
The initial skin lesion with mucocutaneous disease is often notable for its prolonged healing time and large size. In most cases, a healed scar can be identified based on careful examination. Months to years after the initial infection, patients may have rhinorrhea, epistaxis, and nasal congestion.
The lesion commonly arises at the mucocutaneous junction around the nose and may spread inward, destroying tissues and leading to deformity that requires plastic surgery. The lesion heals with scarring, causing the typical tapir or camel nose.
Examination reveals the following features:
Excessive tissue obstructing the nares, septal granulation, and perforation; nose cartilage may be involved, giving rise to external changes known as parrot's beak or camel's nose
Possible presence of granulation, erosion, and ulceration of the palate, uvula, lips, pharynx, and larynx, with sparing of the bony structures; hoarseness may be a sign of laryngeal involvement
Optical and genital mucosal involvement in severe cases
Death occurs from suffocation secondary to airway obstruction, respiratory infection, and aspiration pneumonia. See the following image.
Visceral and viscerotropic disease may manifest with the following physical findings:
Visceral leishmaniasis (kala-azar): Potentially lethal widespread systemic disease characterized by darkening of the skin as well as the pentad of fever, weight loss, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia
Viscerotropic leishmaniasis: Nonspecific abdominal tenderness; fever, rigors, fatigue, malaise, nonproductive cough, intermittent diarrhea, headache, arthralgias, myalgias, nausea, adenopathy, transient hepatosplenomegaly
Patients with visceral leishmaniasis appear thin and cachetic with abdominal distention and protuberance due to massive hepatosplenomegaly (secondary to compensatory production of phagocytic blood cells) (see the image below). The liver and spleen are usually soft and easily palpated in acute disease, with splenic extension to well below the costal margin, and the patient may experience intermittent abdominal distress. Jaundice with mildly elevated enzyme levels is rarely seen and is considered a bad prognostic sign.
Epistaxis and petechiae and ecchymosis from severe thrombocytopenia may occur. Anemia is normochromic and normocytic and caused by various factors, including replacement of marrow by the parasites, splenic sequestration, hemorrhage, hemodilution, and hemolysis. Leukopenia is also observed and may contribute to secondary infections. Thrombocytopenia contributes to the hemorrhagic tendency observed in some cases.
Lymphadenopathy is observed in the African and Chinese forms but is rarely observed in the Indian form. Pedal edema is more common in children. Hair changes, such as alopecia and eyelash elongation, may be present. As the disease progresses, characteristic patchy darkening of the face and trunk has been described and may also affect the hands and feet.
Skin lesions that contain parasites and appear as diffuse, warty, nonulcerative lesions may occur in visceral leishmaniasis, especially in Africa. Although uncommon, xerosis may occur. Complications of visceral leishmaniasis include amyloidosis, glomerulonephritis, and cirrhosis.
In patients with human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection, other atypical findings include gastrointestinal and respiratory involvement. Patients have presented with gastrointestinal ulcerations, masses, pleural effusions, and odynophagia. Spread outside of the reticuloendothelial system appears more common.
Unusual clinical presentations of visceral leishmaniasis include the following:
Pancytopenia without splenomegaly
Generalized lymphadenopathy without hepatosplenomegaly
Massive hepatic necrosis
Chronic liver disease
Retinal hemorrhages (reported in immunodeficient patients)
World Health Organization. Leishmaniasis: the disease and its epidemiology. Available at http://www.who.int/leishmaniasis/disease_epidemiology/en/. Accessed: April 10, 2014.
Centers for Disease Control and Prevention. Parasites home: leishmaniasis. Epidemiology & risk factors. Available at http://www.cdc.gov/parasites/leishmaniasis/epi.html. Accessed: April 11, 2014.
Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 2006 Feb. 90(2):85-91. [Medline].
Cardo LJ, Salata J, Harman R, Mendez J, Weina PJ. Leukodepletion filters reduce Leishmania in blood products when used at collection or at the bedside. Transfusion. 2006 Jun. 46(6):896-902. [Medline].
McHugh CP, Melby PC, LaFon SG. Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. Am J Trop Med Hyg. 1996 Nov. 55(5):547-55. [Medline].
Centers for Disease Control and Prevention. Parasites home: leishmaniasis. Resources for health professionals. Available at http://www.cdc.gov/parasites/leishmaniasis/health_professionals/. Accessed: April 10, 2014.
Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med. 1993 May 13. 328(19):1383-7. [Medline].
Coleman RE, Burkett DA, Putnam JL, Sherwood V, Caci JB, Jennings BT, et al. Impact of phlebotomine sand flies on U.S. Military operations at Tallil Air Base, Iraq: 1. background, military situation, and development of a "Leishmaniasis Control Program". J Med Entomol. 2006 Jul. 43(4):647-62. [Medline].
Myles O, Wortmann GW, Cummings JF, Barthel RV, Patel S, Crum-Cianflone NF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007 Sep 24. 167(17):1899-901. [Medline].
Centers for Disease Control and Prevention. Update: Cutaneous leishmaniasis in U.S. military personnel--Southwest/Central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004 Apr 2. 53(12):264-5. [Medline].
Leishmaniasis Fact Sheet. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs375/en/. 2016 Mar 01; Accessed: 2016 Mar 31.
Leishmaniasis - Global Health Observatory Data. World Health Organization. Available at http://apps.who.int/gho/data/node.main.NTDLEISH?lang=en. 2016 Mar 01; Accessed: 2016 Mar 31.
South-East Asia poised to defeat visceral leishmaniasis (kala-azar). WORLD HEALTH ORGANIZATION. Available at http://www.who.int/neglected_diseases/news/SEARO_poised_to_defeat_VL/en/. 2015 OCT 15; Accessed: 2016 MAR 31.
World Health Organization. Essential leishmaniasis maps: visceral and mucocutaneous leishmaniasis. April 10, 2014. [Full Text].
Martín-Ezquerra G, Fisa R, Riera C, Rocamora V, Fernández-Casado A, Barranco C, et al. Role of Leishmania spp. infestation in nondiagnostic cutaneous granulomatous lesions: report of a series of patients from a Western Mediterranean area. Br J Dermatol. 2009 Aug. 161(2):320-5. [Medline].
Monno R, Giannelli G, Rizzo C, De Vito D, Fumarola L. Recombinant K39 immunochromatographic test for diagnosis of human leishmaniasis. Future Microbiol. 2009 Mar. 4(2):159-70. [Medline].
Kubar J, Fragaki K. Recombinant DNA-derived leishmania proteins: from the laboratory to the field. Lancet Infect Dis. 2005 Feb. 5(2):107-14. [Medline].
Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health. 2001 Feb. 6(2):108-13. [Medline].
Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol. 2001 Nov. 8(6):1220-4. [Medline].
Lemos EM, Carvalho SF, Corey R, Dietze R. [Evaluation of a rapid test using recombinant k39 antigen in the diagnosis of visceral leishmaniasis in Brazil]. Rev Soc Bras Med Trop. 2003. 36 Suppl 2:36-8. [Medline].
Hartzell JD, Aronson NE, Weina PJ, Howard RS, Yadava A, Wortmann GW. Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis. Am J Trop Med Hyg. 2008 Dec. 79(6):843-6. [Medline].
Singh D, Pandey K, Das VN, Das S, Kumar S, Topno RK, et al. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. J Clin Microbiol. 2009 Aug. 47(8):2684-5. [Medline]. [Full Text].
Alam MZ, Shamsuzzaman AK, Kuhls K, Schönian G. PCR diagnosis of visceral leishmaniasis in an endemic region, Mymensingh district, Bangladesh. Trop Med Int Health. 2009 May. 14(5):499-503. [Medline].
Wortmann G, Hochberg L, Houng HH, Sweeney C, Zapor M, Aronson N, et al. Rapid identification of Leishmania complexes by a real-time PCR assay. Am J Trop Med Hyg. 2005 Dec. 73(6):999-1004. [Medline].
Wall EC, Watson J, Armstrong M, Chiodini PL, Lockwood DN. Epidemiology of imported cutaneous leishmaniasis at the Hospital for Tropical Diseases, London, United Kingdom: use of polymerase chain reaction to identify the species. Am J Trop Med Hyg. 2012 Jan. 86(1):115-8. [Medline]. [Full Text].
Ozcan D, Seçkin D, Allahverdiyev AM, Weina PJ, Aydin H, Ozçay F, et al. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis. Pediatr Transplant. 2007 Mar. 11(2):228-32. [Medline].
[Guideline] Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10. 58:1-207; quiz CE1-4. [Medline].
[Guideline] AIDSinfo.com. Clinical guidelines portal. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: what’s new in the guidelines. July 8, 2013. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed: April 14, 2014.
Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992 Mar. 165(3):528-34. [Medline].
Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002 Aug 1. 35(3):261-7. [Medline].
Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11. 362(6):504-12. [Medline].
Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 5. 377(9764):477-86. [Medline].
Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. 2001 Aug 25. 323(7310):419-22. [Medline].
Avasthi R, Chaudhary SC, Khanna S. Visceral leishmaniasis simulating chronic liver disease: successful treatment with miltefosine. Indian J Med Microbiol. 2009 Jan-Mar. 27(1):85-6. [Medline].
Ritmeijer K, Ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, et al. Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV Prevalence. Clin Infect Dis. 2011 Oct 19. [Medline].
Prasad R, Kumar R, Jaiswal BP, Singh UK. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr. 2004 Feb. 71(2):143-4. [Medline].
Impavido (miltefosine) prescribing information. [package insert]. Wilmington, DE: Paladin Therapeutics, Inc. 2014.
Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec. 100 Suppl 1:S26-33. [Medline].
Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg. 2011 Jul. 85(1):66-9. [Medline]. [Full Text].
Investigational Drug Available Directly from CDC for the Treatment of Infections with Free-Living Amebae. MMWR Morb Mortal Wkly Rep. 2013 Aug 23. 62(33):666. [Medline].
Nacher M, Carme B, Sainte Marie D, Couppie P, Clyti E, Guibert P, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001 Jun. 95(4):331-6. [Medline].
Dogra J. Current therapies for treatment of cutaneous leishmaniasis in India. Infection. 1992 Jul-Aug. 20(4):189-91. [Medline].
Ozgoztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol. 1997 Jan. 36(1):61-3. [Medline].
Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002 Mar 21. 346(12):891-5. [Medline].
Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010 Dec 21. 4(12):e912. [Medline]. [Full Text].
Soto J, Toledo JT. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis. 2007 Jan. 7(1):7. [Medline].
Ben Salah A, Ben Massaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013. 368:524-32.
Keller DM. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. Medscape Medical News. February 7, 2013. Available at http://www.medscape.com/viewarticle/778974. Accessed: February 18, 2013.
El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol. 1986 Aug. 87(2):284-8. [Medline].
Braunwald E, Fauci AS, Hauser SL, et al. Leishmaniasis. 15th ed. Harrison's Manual of Medicine. 2001: McGraw-Hill;
Masmoudi A, Dammak A, Chaaben H, Maalej N, Akrout F, Turki H. Doxycycline for the treatment of cutaneous leishmaniasis. Dermatol Online J. 2008 Aug 15. 14(8):22. [Medline].
Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis. 2005 Apr 15. 40(8):1148-55. [Medline].
Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016 Mar 8. 5 (1):19. [Medline].
Sindermann H, Engel KR, Fischer C, Bommer W; Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis. 2004 Nov 15. 39(10):1520-3. [Medline].
Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011 Aug. 15(8):e525-32. [Medline].
Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine. 2005 Apr 22. 23(22):2825-40. [Medline].
Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012 Feb 15. 205(4):684-92. [Medline]. [Full Text].
Brooks M. FDA Clears Miltefosine (Impavido) for Leishmaniasis. Medscape Medical News. Mar 20 2014. [Full Text].
Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997 Apr. 10(2):298-319. [Medline].
World Health Organization. Essential leishmaniasis maps: cutaneous leishmaniasis. Available at http://www.who.int/leishmaniasis/leishmaniasis_maps/en/index1.html. Accessed: April 10, 2014.